RACK1 is a candidate gene associated with the prognosis of patients with early stage non-small cell lung cancer

Background This study was conducted to identify genetic polymorphisms associated with the prognosis of patients with early stage NSCLC. Materials and Methods We genotyped 1,969 potentially functional single nucleotide polymorphisms (SNPs) of 1,151 genes involved in carcinogenesis in 166 NSCLC patients who underwent curative surgery, using the Affymetrix custom-made GeneChip. A replication study was performed in an independent cohort of 626 patients. Results Fifty six SNPs which were associated with both overall survival (OS) and disease-free survival (DFS) with log-rank P values < 0.05 in discovery set were selected for validation. Among those, five SNPs (RACK1 rs1279736C>A and rs3756585T>G, C3 rs2287845T>C, PCAF rs17006625A>G, and PCM1 rs17691523C>G) were found to be significantly associated with survival in the same direction as the discovery set. In combined analysis, the rs1279736C>A and rs3756585T>G were most significantly associated with OS and DFS in multivariate analysis (P for OS = 4 × 10−5 and 7 × 10−5, respectively; and P for DFS = 0.003, both; under codominant model). In vitro promoter assay and electrophoretic mobility shift assay revealed that the rs3756585 T-to-G change increased promoter activity and transcription factor binding of RACK1. Conclusions We identified five SNPs, especially RACK1 rs3756585T>G, as markers for prognosis of patients with surgically resected NSCLC.

[1]  Lijing Yao,et al.  Inferring regulatory element landscapes and transcription factor networks from cancer methylomes , 2015, Genome Biology.

[2]  J. Park,et al.  A Functional Polymorphism in CSF1R Gene Is a Novel Susceptibility Marker for Lung Cancer among Never-Smoking Females , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  Kristen Jepsen,et al.  Identification of Liver Cancer Progenitors Whose Malignant Progression Depends on Autocrine IL-6 Signaling , 2013, Cell.

[4]  T. Haferlach,et al.  Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1 , 2013, Annals of Hematology.

[5]  P. Pineau,et al.  Associations of genetic variants in the transcriptional coactivators EP300 and PCAF with hepatocellular carcinoma. , 2012, Cancer epidemiology.

[6]  E. Androphy,et al.  The histone acetyltransferase PCAF regulates p21 transcription through stress-induced acetylation of histone H3 , 2012, Cell cycle.

[7]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[8]  R. Shoemaker,et al.  Library-free Methylation Sequencing with Bisulfite Padlock Probes , 2012, Nature Methods.

[9]  P. Kiely,et al.  RACK1, A multifaceted scaffolding protein: Structure and function , 2011, Cell Communication and Signaling.

[10]  M. Kolev,et al.  Complement in Cancer and Cancer Immunotherapy , 2011, Archivum Immunologiae et Therapiae Experimentalis.

[11]  Qing-quan Li,et al.  RACK1 promotes breast carcinoma migration/metastasis via activation of the RhoA/Rho kinase pathway , 2011, Breast Cancer Research and Treatment.

[12]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[13]  M. Sughrue,et al.  Cancer and the Complement Cascade , 2010, Molecular Cancer Research.

[14]  Toshihide Matsumoto,et al.  Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas. , 2010, Lung cancer.

[15]  Ying Chen,et al.  The p300/CBP - associated factor is frequently down-regulated in intestinal-type gastric carcinoma and constitutes a biomarker for clinical outcome , 2010, Cancer biology & therapy.

[16]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[17]  Wen-juan Wang,et al.  RACK1: A superior independent predictor for poor clinical outcome in breast cancer , 2009, International journal of cancer.

[18]  L. Tanoue,et al.  The new lung cancer staging system. , 2009, Chest.

[19]  G. Daley,et al.  Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming , 2009, Nature Biotechnology.

[20]  Xiaodong Feng,et al.  RACK1, an excellent predictor for poor clinical outcome in oral squamous carcinoma, similar to Ki67. , 2009, European journal of cancer.

[21]  Peter Bühlmann,et al.  p-Values for High-Dimensional Regression , 2008, 0811.2177.

[22]  John D. Lambris,et al.  Modulation of the anti-tumor immune response by complement , 2008, Nature Immunology.

[23]  Jay Shendure,et al.  Multiplex amplification of large sets of human exons , 2007, Nature Methods.

[24]  P. Donnelly,et al.  Replicating genotype–phenotype associations , 2007, Nature.

[25]  L. Miller,et al.  RACK1 inhibits colonic cell growth by regulating Src activity at cell cycle checkpoints , 2007, Oncogene.

[26]  Peter Horak,et al.  Five genes from chromosomal band 8p22 are significantly down‐regulated in ovarian carcinoma , 2005, Cancer.

[27]  J. Weinstein,et al.  Biomarkers in Cancer Staging, Prognosis and Treatment Selection , 2005, Nature Reviews Cancer.

[28]  Piet Gros,et al.  Structures of complement component C3 provide insights into the function and evolution of immunity , 2005, Nature.

[29]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[30]  Robert Livingston,et al.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.

[31]  H. Zou,et al.  Regularization and variable selection via the elastic net , 2005 .

[32]  John O'Quigley,et al.  Explained randomness in proportional hazards models , 2005, Statistics in medicine.

[33]  Douglas F. Easton,et al.  Association studies for finding cancer-susceptibility genetic variants , 2004, Nature Reviews Cancer.

[34]  Timothy R. Rebbeck,et al.  Assessing the function of genetic variants in candidate gene association studies , 2004, Nature Reviews Genetics.

[35]  Hidde Ploegh,et al.  Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. , 2004, Molecular cell.

[36]  Bengt Bergman,et al.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.

[37]  Daiqing Liao,et al.  PCAF is a coactivator for p73-mediated transactivation , 2003, Oncogene.

[38]  J. Wall,et al.  Haplotype blocks and linkage disequilibrium in the human genome , 2003, Nature Reviews Genetics.

[39]  A. Huttenlocher,et al.  RACK1 regulates integrin-mediated adhesion, protrusion, and chemotactic cell migration via its Src-binding site. , 2003, Molecular biology of the cell.

[40]  A. Merdes,et al.  Assembly of centrosomal proteins and microtubule organization depends on PCM-1 , 2002, The Journal of cell biology.

[41]  G. Schatten,et al.  Arrest of cell cycle progression during first interphase in murine zygotes microinjected with anti-PCM-1 antibodies. , 2002, Cell motility and the cytoskeleton.

[42]  J. Friedman.  Greedy function approximation: A gradient boosting machine. , 2001 .

[43]  G. Plopper,et al.  The WD protein Rack1 mediates protein kinase C and integrin-dependent cell migration. , 2001, Journal of cell science.

[44]  B. Hengerer,et al.  RACK1 IS UP‐REGULATED IN ANGIOGENESIS AND HUMAN CARCINOMAS , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  U. Schindler,et al.  A Gain-of-function Mutation in STAT6* , 2000, The Journal of Biological Chemistry.

[46]  M. Houslay,et al.  The RACK1 Signaling Scaffold Protein Selectively Interacts with the cAMP-specific Phosphodiesterase PDE4D5 Isoform* , 1999, The Journal of Biological Chemistry.

[47]  S. Berger,et al.  p53 Sites Acetylated In Vitro by PCAF and p300 Are Acetylated In Vivo in Response to DNA Damage , 1999, Molecular and Cellular Biology.

[48]  S. Berger,et al.  CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. , 1997, Cancer research.

[49]  R. Evans,et al.  Nuclear Receptor Coactivator ACTR Is a Novel Histone Acetyltransferase and Forms a Multimeric Activation Complex with P/CAF and CBP/p300 , 1997, Cell.

[50]  B. Howard,et al.  A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A , 1996, Nature.

[51]  W. Zimmer,et al.  PCM-1, A 228-kD centrosome autoantigen with a distinct cell cycle distribution , 1994, The Journal of cell biology.

[52]  J. Caldwell,et al.  Cloning of an intracellular receptor for protein kinase C: a homolog of the beta subunit of G proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[53]  K. Nishioka,et al.  THE COMPLEMENT SYSTEM IN TUMOR IMMUNITY: SIGNIFICANCE OF ELEVATED LEVELS OF COMPLEMENT IN TUMOR BEARING HOSTS * , 1976, Annals of the New York Academy of Sciences.

[54]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[55]  R. Tibshirani.  Regression Shrinkage and Selection via the Lasso , 1996 .

[56]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[57]  J. Gmiński,et al.  Immunoglobulins and complement components levels in patients with lung cancer. , 1992, Romanian journal of internal medicine = Revue roumaine de medecine interne.